<DOC>
	<DOCNO>NCT01724086</DOCNO>
	<brief_summary>The purpose study explore efficacy safety TMC647055 , TMC435 , low-dose ritonavir , administer together without ribavirin TMC647055 , TMC435 , low-dose ritonavir administer together GSK233680k without ribavirin limited number patient chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Effectiveness 12-Week Combination Therapy TMC647055 TMC435 With Without GSK23336805 With Pharmacokinetic Enhancer With Without Ribavirin Patients Infected With Chronic Genotype 1 Hepatitis C Virus</brief_title>
	<detailed_description>This study open-label study ( people know identity intervention ) patient chronically infect hepatitis C virus ( HCV ) genotype-1a ( GT1a ) genotype-1b ( GT1b ) ass safety , tolerability efficacy coadministration TMC647055 , TMC435 low-dose ritonavir ( RTV ) , without ribavirin ( RBV ) TMC647055 , TMC435 , RTV administer together GSK233680k without RBV 12 week . Approximately 86 patient enrol study . Patients enrol study chronically infect HCV GT1a ( n=10 ) GT1b ( n=20 ) , either treatment-naive patient ( ie , patient never receive PegIFN [ Pegylated interferon alpha-2a 180 mcg subcutaneous week ] , RBV , approve investigational treatment chronic HCV infection ) patient relapsers prior treatment PegIFN /RBV ( ie , `` relapsers '' patient HCV ribonucleic acid [ RNA ] undetectable last treatment measurement prior PegIFN base regimen least 24 week , HCV RNA detectable within 1 year last medication intake ) . Patients first part study divide 4 panel : Panel 1 consist 10 chronic HCV GT1a infect treatment-naive patients/prior relapsers receive 12 week treatment TMC435 + TMC647055 + low-dose ritonavir ribavirin . Panel 2 consist 20 chronic HCV GT1b infect treatment-naive patients/ prior relapsers randomly allocate 2 arm 1:1 ratio . Arm 1 ( N=10 ) receive TMC435 + TMC647055 + low-dose ritonavir ribavirin . Arm 2 ( N=10 ) receive TMC435 + TMC647055 + low-dose ritonavir . Panel 3 consist 16 chronic HCV GT1a GT1b infect treatment-naïve patients/prior relapsers allocate 2 arm : 8 HCV GT1a patient arm 1 8 HCV GT1b patient arm 2 . Patients Arm 1 receive 12 week treatment TMC435 + TMC647055 + low-dose RTV RBV patient Arm 2 receive 12 week treatment TMC435 + TMC647055 + low-dose RTV . Panel 4 consist 40 chronic HCV GT1a GT1b infect treatment-naïve patients/prior relapsers allocate 2 arm : arm consist 20 patient 8 patient infected HCV GT1b . Patients randomize 1:1 ratio 2 arm whereby randomization stratify genotype . Patients Arm 1 receive 12 week treatment TMC435 + TMC647055 + low-dose RTV + GSK2336805 . Patients Arm 2 receive 12 week treatment TMC435 + TMC647055 + low-dose RTV + GSK2336805 . The planned duration investigational treatment 12 week . Patients Panels 1 , 2 , 3 may receive follow-up treatment 12 week 36 week PegIFNα + RBV ; follow-up treatment principle apply Panel 4 base available proof concept data combination , need additional 12 36-week PegIFN/RBV follow-up therapy expect low evaluate 12-week regimen 3 direct act antiviral agent treatment HCV genotype 1 infection . Safety monitor throughout study</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
	<criteria>Documented chronic genotype 1a genotype 1b hepatitis C virus ( HCV ) infection HCV ribonucleic acid ( RNA ) level &gt; 100,000 IU/mL screen Treatmentnaive document prior relapser previous treatment regimen stop treatment least 3 month screen Liver biopsy within 3 year screen visit elastography result available prior first study drug dose Medically stable base physical examination , medical history , vital sign , electrocardiogram perform screen Body mass index 18.0 32.0 kg/m2 body weight 50 kg Evidence liver cirrhosis liver biopsy presence esophageal varix transient elastography result &gt; 14.6 kPa within 2 year prior first dose Evidence decompensated liver disease define prior history current evidence ascites , hepatic encephalopathy , bleed oesophageal gastric varix Evidence significant liver disease addition hepatitis C ( include limit hepatitis B , drug alcoholrelated cirrhosis , autoimmune hepatitis , hemochromatosis , Wilson 's disease , nonalcoholic steatohepatitis , primary biliary cirrhosis ) Receiving receive HCVspecific direct antiviral agent ( HCV protease inhibitor , HCV nucleoside polymerase inhibitor , HCV nonnucleoside polymerase inhibitor , HCV NS5a inhibitor HCV inhibitor target HCV protein target involve HCV replication cycle Coinfected human immunovirus ( HIV ) 1 HIV2 , nongenotype 1a/1b HCV , hepatitis A B virus infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Chronic hepatitis C-infected patient</keyword>
	<keyword>TMC647055</keyword>
	<keyword>TMC435</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Genotype 1a</keyword>
	<keyword>Genotype 1b</keyword>
	<keyword>GSK2336805</keyword>
</DOC>